Want to see PHVS full AI Analyst Report?
PHVS Stock Chart & Stats
$28.58
-$0.46(-2.39%)
At close: 4:00 PM EST
$28.58
-$0.46(-2.39%)
Day’s Range― - ―
52-Week Range$17.05 - $35.91
Previous CloseN/A
Volume14.65K
Average Volume (3M)347.46K
Market Cap
$2.37B
Enterprise Value$1.78B
Total Cash (Recent Filing)$246.96M
Total Debt (Recent Filing)$738.89K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 19, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding69,863,686
10 Day Avg. Volume329,608
30 Day Avg. Volume347,462
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.73K
Enterprise Value/Ebitda-10.68
Forecast
1Y Price Target
$49.60Price Target Upside73.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline ProgressAdvancing from early trials into pivotal Phase 3 and a planned NDA materially reduces development risk versus earlier-stage peers. Near-term regulatory milestones can transform Pharvaris from a research-stage firm to a commercial biotech, enabling sustainable revenue pathways if approvals succeed and strengthening its competitive position in HAE treatment.
Improved Liquidity / Extended RunwayA funded runway into 2028 provides durable capacity to complete pivotal trials, prepare regulatory filings and build initial commercial infrastructure without immediate financing pressure. This reduces short-term funding risk, allowing management to focus on milestone execution and commercialization planning over multiple quarters.
Low Financial LeverageVery low debt levels limit solvency and interest-rate risks and preserve strategic flexibility for R&D or partnerships. Even as equity has declined from sustained losses, minimal leverage gives the company optionality to pursue business development, acquisitions, or structured financings without being constrained by high fixed obligations.
Bears Say
Pre-revenue Status With Widening LossesOperating without product revenue leaves the company structurally reliant on external capital while losses widen materially. Persistent negative profitability undermines internal funding capacity, raises breakeven uncertainty post-approval, and makes long-term planning contingent on successful regulatory outcomes and later commercial execution.
High And Increasing Cash BurnSustained and growing cash burn creates structural funding vulnerability: delays, enrollment issues, or higher commercialization costs would rapidly erode runway. High cash consumption diverts management focus to financing and heightens dilution or partnership necessity, constraining strategic choices over the medium term.
Reliance On Equity Financing (dilution Risk)Frequent equity raises to fund operations indicate dependence on capital markets, producing recurring dilution risk for shareholders. This structural financing approach can limit long-term returns for existing holders and ties progress to market access; adverse market conditions could impede capital availability and slow development or launch plans.
Pharvaris News
PHVS FAQ
What was Pharvaris N.V.’s price range in the past 12 months?
Pharvaris N.V. lowest stock price was $17.05 and its highest was $35.91 in the past 12 months.
What is Pharvaris N.V.’s market cap?
Pharvaris N.V.’s market cap is $2.37B.
When is Pharvaris N.V.’s upcoming earnings report date?
Pharvaris N.V.’s upcoming earnings report date is Aug 19, 2026 which is in 48 days.
How were Pharvaris N.V.’s earnings last quarter?
Pharvaris N.V. released its earnings results on May 12, 2026. The company reported $0.672 earnings per share for the quarter, beating the consensus estimate of N/A by $0.672.
Is Pharvaris N.V. overvalued?
According to Wall Street analysts Pharvaris N.V.’s price is currently Undervalued.
Does Pharvaris N.V. pay dividends?
Pharvaris N.V. does not currently pay dividends.
What is Pharvaris N.V.’s EPS estimate?
Pharvaris N.V.’s EPS estimate is -0.74.
How many shares outstanding does Pharvaris N.V. have?
Pharvaris N.V. has 69,863,686 shares outstanding.
What happened to Pharvaris N.V.’s price movement after its last earnings report?
Pharvaris N.V. reported an EPS of $0.672 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.408%.
Which hedge fund is a major shareholder of Pharvaris N.V.?
Currently, no hedge funds are holding shares in PHVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.60 (73.55% Upside)
$49.60 (73.55% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.47%
12-Months-Change
Fundamentals
Return on Equity
-67.40%
Trailing 12-Months
Asset Growth
11.71%
Trailing 12-Months
Company Description
Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
PHVS Stock 12 Month Forecast
Average Price Target
$49.60
▲(73.55% Upside)
Technical Analysis
Ownership Overview
2.82% Insiders
7.58% Mutual Funds
64.60% Other Institutional Investors
23.86% Public Companies and
Individual Investors